Access cutting-edge pneumococcal disease treatment through this clinical trial at a research site in Glendale. Study-provided care at no cost to qualified participants.
Access pneumococcal disease specialists in Glendale at no cost
This study follows strict safety protocols and ethical guidelines
All study-related pneumococcal disease treatment provided free
This study is a Phase 3, randomized, modified double-blind study which aims to measure whether PCV21 vaccine (investigational pneumococcal conjugate vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20-valent pneumococcal vaccine (Prevnar 20, licensed pneumococcal conjugate vaccine) when they are administered with routine pediatric vaccines in infants aged from approximately 2 months (42 to 89 days). The study duration per
Sponsor: Sanofi Pasteur, a Sanofi Company
Check if you qualify for this pneumococcal disease clinical trial in Glendale, AZ
If you're searching for pneumococcal disease treatment options in Glendale, AZ, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Glendale research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pneumococcal disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.